Long-term dynamics of the levels of anti-SARS-CoV-2 S-protein IgG antibodies in vaccinated individuals

Drapkina, О. М.; Бернс, С. А.; Gorshkov, A. Yu.; Shishkova, V. N.; Ryzhakova, L. N.; Litinskaya, O. А.; Иванова, А. А.; Veretennikova, A. V.; Bashnyak, V. S.; Tatarevich, E. Yu.

doi:10.15829/1728-8800-2021-3124

Cited by 7 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Дополнительные дозы всех вакцин по сути "напоминают" иммунной системе о вирусном S-белке, повышая как количество, так и специфичность иммунного ответа [36]. В то же время вакцины на основе аденовирусов, такие как "Sputnik V", обладают несколькими механизмами действия, что обусловливает их отличие от других вакцинных платформ:…”

Section: механизмы иммунного ответа при Covid-19unclassified

Booster vaccination against the SARS-CoV-2: mechanisms and efficiency

Berns,

Veremeyev,

Savicheva

et al. 2024

Cardiovasc Ther Prev

Self Cite

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) pandemic was not only a serious challenge for the healthcare system around the world, but also an incentive for intensive research and development for the introduction of innovative technologies and drugs, in particular vaccines against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2). The first vaccination campaigns provided significant protection against severe disease course and hospitalization. However, new SARS-COV-2 variants require further comprehensive research and the introduction of booster vaccination. Booster vaccination is the most important tool for immunostimulation and increase of protection duration against the severe disease course. The study of booster vaccines, including BioNTech/Pfizer, Moderna, Oxford AstraZeneca, Sputnik V, Sinopharm и Covaxin vaccines, sheds light on their unique action mechanisms and contribution to long-term immunity. The analysis of clinical data demonstrates their effectiveness and safety. The review summarizes modern knowledge about booster vaccinations against the COVID-19 with focus on action mechanisms and efficiency. In addition, the immune system function in response to COVID-19 is considered, while the role of memory cells, antibody and cellular immunity reactions are emphasized.

show abstract

Section: механизмы иммунного ответа при Covid-19unclassified

Booster vaccination against the SARS-CoV-2: mechanisms and efficiency

Berns,

Veremeyev,

Savicheva

et al. 2024

Cardiovasc Ther Prev

Self Cite

View full text Add to dashboard Cite

show abstract

“…Безопасность и иммуногенность отечественных вакцин «Гам-КОВИД-Вак и «КовиВак» подтверждена в нескольких работах в рамках проспективного исследования «СИРИУС» («Состояние Иммунной системы и исходы у лиц, вакциниРованных протИв вирУСа SARS-CoV-2»). Так, показано, что после введения данных вакцин определен достоверный прирост уровня IgG-антител (АТ) к S-белку вируса SARS-CoV-2 [2].…”

Section: ключевые словаunclassified

Booster vaccination against SARS-CoV-2: current challenges and solutions

Drapkina

Бернс

Gorshkov

et al. 2022

Kompleks. probl. serdečno-sosud. zabol.

Self Cite

View full text Add to dashboard Cite

Highlights. Nowadays the only way to prevent a new coronavirus infection is vaccination. Overcoming such problems as a gradual decrease in the effectiveness of post-vaccination immunity and the emergence of new strains of SARS-CoV-2 is possible due to booster vaccination. The review highlights the current data on the effectiveness and immunogenicity of various booster vaccination regimens and prospects for studying this issue in the Russian Federation.Abstract. The COVID-19 pandemic is going on, which makes it crucial to prevent the spread of coronavirus disease. Vaccination is the only way of specific prevention of COVID-19. The SARS-CoV-2 virus is continuously evolving and new variants appear. Moreover, the effectiveness of protective immunity after vaccination tends to decrease over several months. Booster vaccination may be the solution to these problems. The booster is an extra vaccination that helps to reactivate the immunity against COVID-19. Booster doses can be homologous (the same as the primary vaccine) and heterologous (different from the primary vaccine). It is of current interest to study heterologous vaccination as the injection of different vaccines may result in a more intense immune response. Furthermore, the same vaccine may not be available at the time of booster vaccination. This review is aimed at summarizing the key research findings in the field of booster vaccination against COVID-19.

show abstract

Immunological Potency, Efficacy, and Tolerance of “Gam-COVID-Vac” Vaccine among Students: Prospective Study

et al. 2022

View full text Add to dashboard Cite

Background. Students, as the most active and mobile part of population, often unite into educational and informal groups, move to other regions or countries, and present a specific risk group for the spread of new coronavirus infection. Thus, they require preventive vaccination.Objective. The aim of the study is to study the immunological potency, tolerance, and efficacy of Gam-COVID-Vac vaccine among students of Krasnodar.Methods. 119 seronegative students (18-30 years old) were examined. SARS-CoV-2 IgG (ELISA method) was determined 1, 3, and 6 months after two completed rounds of vaccination. Post-vaccination adverse events and COVID-19 cases were evaluated in the study.Results. SARS-CoV-2 IgG level 1 month after vaccination ranged from 6.15 to 19.38 and was to 16.39 (AU/mL) ±1,12. Immunological potency values ranged from 4.407 to 21.5 (AU/mL) (14.74 ± 2.93) 3 months after. IgG titers were in the range of 4.14 to 17.71 (AU/mL) (10.97 ± 4.69) 6 months after. Adverse events after vaccination were revealed in 34 respondents (28.6%). Among them, local (hyperemia, pain, edema) — 21 (17.6%): slight — 90.4%, major — 9.6%; general (fever, weakness, algor, headache, arthralgia, myalgia) — 13 (10.9%): slight — 69.2%, major — 30.8%. The increase in vaccination coverage in students from 30.3 to 79.1% reduced the COVID-19 morbidity from 3.81 to 1.57%.Conclusion. Gam-COVID-Vac vaccine induced stable humoral response, demonstrated sufficient safety, and reduced morbidity 2.4-fold.

show abstract

Long-term dynamics of the levels of anti-SARS-CoV-2 S-protein IgG antibodies in vaccinated individuals

Cited by 7 publications

References 7 publications

Booster vaccination against the SARS-CoV-2: mechanisms and efficiency

Booster vaccination against the SARS-CoV-2: mechanisms and efficiency

Booster vaccination against SARS-CoV-2: current challenges and solutions

Immunological Potency, Efficacy, and Tolerance of “Gam-COVID-Vac” Vaccine among Students: Prospective Study

Contact Info

Product

Resources

About